New research grant aims to improve genetic diagnostics in individuals with CAPN3 mutations

C3 is excited to share that a research grant has been awarded to Dr. Svetlana Gorokhova and Dr. Marc Bartoli, Translational Neuromyology Team, Marseille Medical Genetics Institute at Aix Marseille University. The project, “Optimizing the functional assay to identify novel CAPN3 variants responsible for the dominant form of calpainopathy,” will develop a tool to help identify the inheritance patterns of CAPN3 variants….

Read More

New Research Grant: Investigating calcium handling modulation as a potential therapeutic for LGMD2A/R1

Coalition to Cure Calpain 3 (C3) is driving LGMD2A/R1 research by awarding a new grant to Dr. Elisabeth Barton, Dr. Lan Wei-LaPierre, and Dr. Siobhan Malany of the University of Florida. The project is titled “Store-operated calcium entry modulation as a potential therapeutic for LGMD2A/R1.” This research is co-funded with the Muscular Dystrophy Association (MDA)….

Read More

New Research Grant: Multi-national collaboration aims to identify biomarkers

C3 is pleased to announce the funding of a new research project to Dr. Christopher Heier, of Virginia Commonwealth University in the USA, and Dr. Utkarsh Dang, of Carleton University in Canada. The project is titled “Comparative proteomics of LGMD2A/R1 and Becker muscular dystrophy to develop serum protein biomarkers and predict drug responsiveness in LGMD2A/R1.”…

Read More

New research alert! Measuring motor function in LGMD2A/R1

A new paper, “Motor Function in LGMD2A/R1: Validation of Clinical Outcome Assessments for Clinical Care and Trial Readiness,” was recently published in the journal Neurology: Genetics. This important, C3-funded initiative is a testament to international cooperation, bringing together leading LGMD researchers. They leveraged clinical data collected from 92 individuals with LGMD2A/R1, ultimately advancing the understanding of how…

Read More

New Publication Characterizes Mouse Model of Calpainopathy

A group of researchers from the Heimer Institute for Muscle Research in Bochum, Germany have characterized a Capn3-deficient mouse strain. This is one of four strains recently generated by Jackson Laboratories as part of a Coalition to Cure Calpain 3 research grant. This descriptive study analyzed wildtype (WT) and Capn3-deficient (C3) mice of both genders…

Read More

What’s new in LGMD2A/R1 research? Posters highlight new research at the International LGMD Conference

The 2025 International LGMD Conference, hosted by the Speak Foundation, was attended by over 500 LGMD patients and family members, clinicians, and scientists. For the first time, the conference included a scientific poster session for researchers to present their basic, translational, or clinical research related to LGMDs. Twenty-five abstracts were selected for presentations, including seven that were…

Read More

LGMD2A/R1 Standards of Care Workshop

Coalition to Cure Calpain 3 (C3) is proud to have partnered with the John Walton Muscular Dystrophy Research Centre, Sarepta Therapeutics, the Speak Foundation, and LGMD Awareness Foundation to sponsor the LGMD2A/R1 Standards of Care (SOC) Workshop. This meeting, organized by Dr. Volker Straub, Director of the John Walton Muscular Dystrophy Research Centre at Newcastle…

Read More

New Research Alert: GRASP-001 Study

A team of LGMD researchers, called the GRASP-LGMD Consortium, published the baseline results of their LGMD2A/R1 clinical outcome study in the Annals of Clinical and Translational Neurology. The study, which was funded in part by a research grant from Coalition to Cure Calpain 3, enrolled 42 individuals across 11 international sites. Each participant completed several measures of their…

Read More